+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Effects of intensive versus mild lipid lowering by statins in patients with ischemic congestive heart failure: Korean Pitavastatin Heart Failure (SAPHIRE) study



Effects of intensive versus mild lipid lowering by statins in patients with ischemic congestive heart failure: Korean Pitavastatin Heart Failure (SAPHIRE) study



Korean Journal of Internal Medicine 29(6): 754-763



This study was designed to evaluate the dose-effect relationship of statins in patients with ischemic congestive heart failure (CHF), since the role of statins in CHF remains unclear. The South koreAn Pitavastatin Heart FaIluRE (SAPHIRE) study was designed to randomize patients with ischemic CHF into daily treatments of 10 mg pravastatin or 4 mg pitavastatin. The low density lipoprotein cholesterol level decreased by 30% in the pitavastatin group compared with 12% in the pravastatin (p < 0.05) group. Left ventricular systolic dimensions decreased significantly by 9% in the pitavastatin group and by 5% in the pravastatin group. Left ventricular ejection fraction (EF) improved significantly from 37% to 42% in the pitavastatin group and from 35% to 39% in the pravastatin group. Although the extent of the EF change was greater in the pitavastatin group (16% vs. 11%) than that in the pravastatin group, no significant difference was observed between the groups (p = 0.386). Exercise capacity, evaluated by the 6-min walking test, improved significantly in the pravastatin group (p < 0.001), but no change was observed in the pitavastatin group (p = 0.371). Very low dose/low potency pravastatin and high dose/high potency pitavastatin had a beneficial effect on cardiac reverse remodeling and improved systolic function in patients with ischemic CHF. However, only pravastatin significantly improved exercise capacity. These findings suggest that lowering cholesterol too much may not be beneficial for patients with CHF.

(PDF emailed within 1 workday: $29.90)

Accession: 052871895

Download citation: RISBibTeXText

PMID: 25378974


Related references

Cost effectiveness of intensive lipid-lowering treatment for patients with congestive heart failure and coronary heart disease in the US. Pharmacoeconomics 28(1): 47-60, 2010

High-sensitivity assay of plasma cardiac troponin T predicts the effects of pitavastatin in patients with chronic heart failure: a sub-group analysis from the pitavastatin heart failure study (PEARL). European Heart Journal 34(Suppl 1): P3294-P3294, 2013

Rationale and design of a study to evaluate effects of pitavastatin on Japanese patients with chronic heart failure: the pitavastatin heart failure study (PEARL study). International Journal of Cardiology 156(2): 144-147, 2012

Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol 125 mg/dl treated with statins versus no lipid-lowering drug. American Journal of Cardiology 90(2): 147-149, 2002

Effects of pitavastatin in Japanese patients with chronic heart failure: the Pitavastatin Heart Failure Study (PEARL Study). Circulation Journal 77(4): 917-925, 2013

Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol gtoreq125 mg/dl treated with statins versus no lipid-lowering drug. American Journal of Cardiology 90(2): 147-149, July 15, 2002

Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. Circulation 92(2): 212-218, 1995

Is non-sustained ventricular tachycardia an independent predictor of 1 year mortality also in patients with mild and moderate congestive heart failure? The Italian Network Congestive Heart Failure database. European Heart Journal 19(ABST SUPPL ): 513, 1998

Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. The Pacing Therapies for Congestive Heart Failure Study Group. The Guidant Congestive Heart Failure Research Group. Circulation 99(23): 2993-3001, 1999

Comparative trial of quinapril versus captopril in mild to moderate congestive heart failure. Quinapril/Captopril Congestive Heart Failure Study Group. Journal of Hypertension. Supplement 12(4): S89-S93, 1994

Beyond lipid lowering: pleiotropic effects of statins in heart failure. Netherlands Heart Journal 21(9): 406-407, 2013

Dose-related effects of ACE inhibition in man: quinapril in patients with moderate congestive heart failure. The Study Group on Neurohormonal Regulation in Congestive Heart Failure: Lausanne, Switzerland; Berlin, Düsseldorf, Munich, Germany. European Heart Journal 15 Suppl D: 113-122, 1994

Review of heart failure events in the antihypertensive and lipid lowering treatment to prevent heart attack trial ALLHAT heart failure validation Study. Circulation 108(17 Supplement): IV-399-IV-400, October 28, 2003

Hospital-based comprehensive cardiac rehabilitation versus usual care among patients with congestive heart failure, ischemic heart disease, or high risk of ischemic heart disease: 12-month results of a randomized clinical trial. American Heart Journal 155(6): 1106-1113, 2008

Congestive heart failure is associated with lipoprotein components in statin-treated patients with coronary heart disease Insights from the Incremental Decrease in End points Through Aggressive Lipid Lowering Trial (IDEAL). Atherosclerosis 205(2): 522-527, 2009